Your browser doesn't support javascript.
loading
Cell therapy strategies for COVID-19: Current approaches and potential applications.
Zaki, Mark M; Lesha, Emal; Said, Khaled; Kiaee, Kiavash; Robinson-McCarthy, Lindsey; George, Haydy; Hanna, Angy; Appleton, Evan; Liu, Songlei; Ng, Alex H M; Khoshakhlagh, Parastoo; Church, George M.
Afiliação
  • Zaki MM; GC Therapeutics Inc., Cambridge, MA 02139, USA.
  • Lesha E; Department of Neurosurgery, University of Michigan, 1500 E Medical Center Dr., Ann Arbor, MI 48109, USA.
  • Said K; GC Therapeutics Inc., Cambridge, MA 02139, USA.
  • Kiaee K; Department of Neurosurgery, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
  • Robinson-McCarthy L; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
  • George H; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
  • Hanna A; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
  • Appleton E; GC Therapeutics Inc., Cambridge, MA 02139, USA.
  • Liu S; Department of Medicine, Beaumont Hospital, Royal Oak, MI, USA.
  • Ng AHM; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
  • Khoshakhlagh P; Wyss Institute for Biologically Inspired Engineering, Harvard University, Cambridge, MA 02115, USA.
  • Church GM; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
Sci Adv ; 7(33)2021 Aug.
Article em En | MEDLINE | ID: mdl-34380619
ABSTRACT
Coronavirus disease 2019 (COVID-19) continues to burden society worldwide. Despite most patients having a mild course, severe presentations have limited treatment options. COVID-19 manifestations extend beyond the lungs and may affect the cardiovascular, nervous, and other organ systems. Current treatments are nonspecific and do not address potential long-term consequences such as pulmonary fibrosis, demyelination, and ischemic organ damage. Cell therapies offer great potential in treating severe COVID-19 presentations due to their customizability and regenerative function. This review summarizes COVID-19 pathogenesis, respective areas where cell therapies have potential, and the ongoing 89 cell therapy trials in COVID-19 as of 1 January 2021.
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Sci Adv Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Sci Adv Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos